Other Events ·
On June 10, 2026, stockholders approved an amendment to the Certificate of Incorporation to increase the number of…
SLDBSolid Biosciences Inc.
On June 10, 2026, stockholders approved an amendment to the Certificate of Incorporation to increase the number of authorized shares of common stock from 240,000,000 to 480,000,000. The company filed the Certificate of Amendment with the Secretary of State of Delaware on the same day. Other meeting outcomes included the election of Class II directors Clare Kahn, Adam Stone, and Lynne Sullivan, the advisory ratification of Ilan Ganot as a Class I director, the ratification of PricewaterhouseCoopers LLP as independent auditor, and the approval of executive compensation. Solid Biosciences Inc. is a biotechnology company that develops genetic medicines for rare diseases.